8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 18, 2024)

Filed July 18, 2024For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on July 18, 2024, to announce its second quarter 2024 financial results. The filing primarily incorporates a press release containing the detailed financial performance for the quarter. Investors should note that Abbott utilizes non-GAAP financial measures alongside GAAP measures to provide a clearer view of ongoing operational performance. These non-GAAP metrics exclude items such as acquisition-related expenses, restructuring costs, and amortization, which management believes offer better insight into the company's core business operations.

Key Highlights

  • 1Abbott Laboratories announced its second quarter 2024 financial results on July 18, 2024.
  • 2The 8-K filing incorporates a press release (Exhibit 99.1) with the detailed financial results.
  • 3The company utilizes non-GAAP financial measures to present its results, alongside GAAP measures.
  • 4Non-GAAP measures exclude items like acquisition costs, restructuring actions, and amortization to highlight ongoing business performance.
  • 5Management believes these non-GAAP measures offer investors a better evaluation of the company's core operations.
  • 6Investors are advised to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financial measures.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the second quarter of 2024, as detailed in an accompanying press release.

Abbott uses both Generally Accepted Accounting Principles (GAAP) financial measures and various non-GAAP financial measures in its earnings release. The non-GAAP measures are adjusted to exclude certain unusual or unpredictable items.

Abbott presents non-GAAP financial measures to provide investors with a clearer understanding of the company's ongoing business performance by excluding items such as acquisition-related expenses, restructuring costs, and intangible amortization, which management uses internally to assess performance.

Investors should consider Abbott's non-GAAP financial measures in addition to, and not as a substitute for, the financial measures prepared in accordance with GAAP. This ensures a comprehensive view of the company's financial health.